ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP™)
June 16 2021 - 6:33AM
Business Wire
New preclinical research in mice finds
nicotinamide riboside (NR) prevented loss of bone mass, reduced
neuroinflammation, and reduced the negative effects of
alcohol-induced inflammation
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of
four recently published preclinical studies, highlighting new
findings for its patented nicotinamide riboside (NR) healthy aging
nutrient.
Through the industry-leading ChromaDex External Research Program
(CERP™), ChromaDex provides its patented NR ingredient, Niagen®,
technological and scientific expertise to research institutions and
universities at no cost. ChromaDex continues to support NAD+
research through CERP and has developed a global community of
esteemed researchers exploring the potential impact of nicotinamide
riboside and NAD+ on health. The program has amassed over 225
research agreements which have resulted in 12 published clinical
studies and 66 published preclinical studies.
“The body of clinical and preclinical evidence supporting the
impact of nicotinamide riboside and NAD+ elevation on a variety of
health outcomes continues to grow at a rapid pace,” says Dr. Andrew
Shao, ChromaDex Senior Vice President of Global Scientific &
Regulatory Affairs. “We look forward to additional studies on NR to
build upon the existing foundation of evidence.”
A first-of-its-kind preclinical study found that NR
administration prevented the loss of bone mass in aging mice. The
study was conducted by researchers at the University of Arkansas
for Medical Sciences (UAMS) and the results were published in the
journal Aging and Mechanisms of Disease, part of Nature Partner
Journals. This was the first study to investigate and demonstrate a
beneficial impact of NR on bone health, by exploring how the
Sirt1/FoxO/β-catenin gene pathway in bone stem cells changes with
aging.
In another novel preclinical study, NR restored youthful
metabolic capacity of aged hematopoietic stem cells (HSCs) and
shifted the cellular composition of aged bone marrow back towards
that of young mice. The study was conducted by researchers at the
Australian Regenerative Medicine Institute (ARMI) at Monash
University and the results were published in Nature Communications.
This was the first study to explore and reveal the potential
benefits of NR on blood stem cell health in aged mice. More
research is needed to determine whether NR supplementation may help
counteract such age-associated changes in humans.
A new preclinical study suggests boosting NAD+ helps reduce
neuroinflammation in mice. The study was conducted by researchers
at Kanazawa University in Japan and the results were published in
the Journal of Neurochemistry. The findings reinforce previous data
from earlier preclinical studies demonstrating the enzyme CD38
depletes NAD+ levels and deletion of CD38 may help reduce
neuroinflammation. Importantly, this study showed boosting NAD+
levels both through inhibition of CD38 and supplementation of NR
directly suppressed neuroinflammation in the brain.
Finally, a new in vitro study demonstrated that NR reduced the
harmful effects of alcohol on macrophages. The study was conducted
by researchers at the University of Connecticut and the results
were published in Laboratory Investigation. Consistent with
previous studies, NR increased NAD+ and SIRT1 expression, thereby
resulting in a significant decrease in alcohol-induced inflammation
and oxidative stress.
ChromaDex has invested over $35 million in investigating,
manufacturing and offering NR in the form of Niagen® and has
secured more than 20 patents. ChromaDex has demonstrated the safety
and/or efficacy of Niagen® in 12 published human trials (and nearly
40 additional ongoing studies further evaluating its safety and
efficacy) and has achieved government regulatory acceptance in the
United States, Canada, the European Union, and Australia.
For additional information on the science supporting Niagen®
(patented nicotinamide riboside) visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210616005185/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2023 to Sep 2024